News

Frazier's biotech SPAC files first 10-Q after $75M IPO

What's the deal? Frazier Life Sciences Acquisition Corp. II filed its first Form 10-Q on November 17, 2026, reporting formation-stage financials and confirming a $75 million IPO. The Cayman Islands blank-check company, sponsored by Frazier Life Sciences Holdings II, listed on Nasdaq under "FLSC" and plans to pursue a merger in the biotechnology sector.

By the numbers: The IPO, which closed October 15, sold 7,500,000 Class A shares at $10.00 each for $75 million in gross proceeds. A concurrent private placement of 300,000 shares added $3 million. Offering costs totalled $4,111,319, including $3 million in deferred underwriting commissions.

Formation financials: For the period from its August 7 inception through September 30, the company reported a net loss of $112,569 and a shareholders' deficit of $87,569, with no operating activity. It drew $200,000 on a promissory note from its sponsor to fund setup.

What's the endgame? The company, led by chief executive officer Albert Cha, aims to merge with a business that can develop new therapies for patients. It has not identified a target or held substantive talks, so the proceeds sit in trust pending a deal.

Why now? Dedicated biotech SPACs are finding renewed footing in a stronger 2026 market. Through the third quarter, biotech IPOs raised $7.5 billion across 22 offerings, exceeding full-year totals for each of 2022 through 2025, while SPAC issuance also climbed.

The signal: Frazier II's $75 million trust is modest next to larger comparable deals, such as Corxel's proposed merger with Amanat backed by a planned $300 million PIPE. Until it names a target, this is a funding vehicle, not new operating capital for a drug developer — a bet that SPAC capital can again route into biotech listings.

Read more: kalkinemedia.com

Image credit: Generated with Gemini

More top stories